Becton Dickinson Cash Flow from Operating Activities 2012-2026 | BDX
Becton Dickinson annual/quarterly cash flow from operating activities history and growth rate from 2012 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Becton Dickinson cash flow from operating activities for the quarter ending March 31, 2026 was $657M, a 5.19% decline year-over-year.
- Becton Dickinson cash flow from operating activities for the twelve months ending March 31, 2026 was $7.020B, a 18.11% decline year-over-year.
- Becton Dickinson annual cash flow from operating activities for 2025 was $3.43B, a 10.77% decline from 2024.
- Becton Dickinson annual cash flow from operating activities for 2024 was $3.844B, a 28.56% increase from 2023.
- Becton Dickinson annual cash flow from operating activities for 2023 was $2.99B, a 21% increase from 2022.
|
Becton Dickinson Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $3,430 |
| 2024 | $3,844 |
| 2023 | $2,990 |
| 2022 | $2,471 |
| 2021 | $4,126 |
| 2020 | $2,937 |
| 2019 | $3,330 |
| 2018 | $2,865 |
| 2017 | $2,550 |
| 2016 | $2,559 |
| 2015 | $1,730 |
| 2014 | $1,746 |
| 2013 | $1,717 |
| 2012 | $1,693 |
| 2011 | $1,638 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |